Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum ...

Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...

Feb 25 (Reuters) - Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well ...

DENVER -- A daily, single-tablet combination of bictegravir and lenacapavir (Yeztugo) was noninferior to complex multi-tablet ...

Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could ...

ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, VH184 and VH499.

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...

As GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV prevention and treatment field, the company is reinforcing the staying power of its long-acting treatment Cabenuva | ...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...

Children with HIV on dolutegravir (Tivicay)-based antiretroviral therapy (ART) can safely receive the standard prophylactic ...

While there are fewer men living with HIV than women, data shows that more men die of Aids. Experts and organisations ...